0.45
0.00%
+0.00
After Hours:
.44
-0.01
-2.22%
Scinai Immunotherapeutics Ltd ADR stock is currently priced at $0.45, with a 24-hour trading volume of 19,082.
It has seen a +0.00% increased in the last 24 hours and a +0.47% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $0.4457 pivot point. If it approaches the $0.4543 resistance level, significant changes may occur.
Previous Close:
$0.45
Open:
$0.4461
24h Volume:
19,082
Market Cap:
$2.62M
Revenue:
-
Net Income/Loss:
$-9.29M
P/E Ratio:
-0.1484
EPS:
-3.0332
Net Cash Flow:
$-9.42M
1W Performance:
-4.26%
1M Performance:
+0.47%
6M Performance:
-28.57%
1Y Performance:
+0.00%
Scinai Immunotherapeutics Ltd ADR Stock (SCNI) Company Profile
Name
Scinai Immunotherapeutics Ltd ADR
Sector
Industry
Phone
972 8 930 2529
Address
Jerusalem BioPark Building, 2nd floor Hadassah Ein Kerem Campus, Jerusalem
Scinai Immunotherapeutics Ltd ADR Stock (SCNI) Latest News
Scinai Immunotherapeutics Showcases Growth and Innovation - TipRanks.com - TipRanks
TipRanks
Scinai Publishes FY 2023 Financial Statements, Files Annual Report on Form 20-F and Provides Business Update - Marketscreener.com
Marketscreener.com
Scinai Immunotherapeutics Battles Nasdaq Delisting - TipRanks.com - TipRanks
TipRanks
Scinai Immunotherapeutics enacts reverse split to meet Nasdaq rules - Investing.com
Investing.com
Scinai Immunotherapeutics Ltd ADR Stock (SCNI) Financials Data
Scinai Immunotherapeutics Ltd ADR (SCNI) Net Income 2024
SCNI net income (TTM) was -$9.29 million for the quarter ending September 30, 2023, a -4,990% decrease year-over-year.
Scinai Immunotherapeutics Ltd ADR (SCNI) Cash Flow 2024
SCNI recorded a free cash flow (TTM) of -$9.42 million for the quarter ending September 30, 2023, a +31.34% increase year-over-year.
Scinai Immunotherapeutics Ltd ADR (SCNI) Earnings per Share 2024
SCNI earnings per share (TTM) was -$5.20 for the quarter ending September 30, 2023, a -783.00% decline year-over-year.
About Scinai Immunotherapeutics Ltd ADR
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Cap:
|
Volume (24h):